Bayer will pay up to $1.3 billion to license Kumquat Biosciences' KRAS G12D inhibitor, targeting hard-to-treat cancers like pancreatic, colorectal, and lung. While Bayer sees it as a key oncology push, retail sentiment on Stocktwits turned bearish. The drug enters Phase Ia trials soon, aiming at a mutation with no approved treatment despite its aggressive prevalence.